



1st announcement

6th Heidelberg Myeloma Workshop

Current status and developments in diagnosis and therapy of multiple myeloma

Congress venue:

Lecture hall, Klinik für Innere Medizin
Universitätsklinikum Heidelberg

Friday, May 5th 2017

Saturday, May 6th 2017

Prof. Dr. med. Hartmut Goldschmidt

Prof. Dr. med. Jens Hillengass

PD Dr. med. Marc-Steffen Raab

Prof. Dr. med. Carsten Müller-Tidow

Prof. Dr. med. Dirk Jäger

Prof. Dr. med. Christof von Kalle




UniversitätsKlinikum Heidelberg



NATIONALES CENTRUM
FÜR TUMORERKRANKUNGEN
HEIDELBERG

getragen von:
Deutsches Krebsforschungszentrum
Universitätsklinikum Heidelberg
Thorasklinik Heidelberg
Deutsche Krebshilfe



6th Heidelberg Myeloma Workshop

Current status and developments in
diagnosis and therapy of multiple myeloma

Friday, 5th of May

9:00 a.m. – 11:10 a.m.

Congress Venue: NCT Heidelberg, Room K2/K3,
Im Neuenheimer Feld 460

PRE-CONFERENCE SCIENTIFIC WORKSHOP on bone metabolism and bone substitute materials (related to the SFB Transregio 79)

Chairmen: Dirk Hose, Heidelberg/Christian Heiss, Gießen

9:00 a.m. – 9:10 a.m.

Opening remarks

Hartmut Goldschmidt, Heidelberg

9:10 a.m. – 9:30 a.m.

Pathophysiology of bone disease in multiple myeloma

Franz Jakob, Würzburg

9:30 a.m. – 9:50 a.m.

Interaction of bone disease and bone marrow micro- environment

Ulf Müller-Ladner, Gießen

9:50 a.m. – 10:10 a.m.

Prevention and treatment of malignant bone disease

Lorenz C. Hofbauer, Dresden

10:10 a.m. – 10:30 a.m.

Surgical treatment for benign and malignant bone defects

Christian Heiss, Gießen

10:30 a.m. – 10:50 a.m.

Development of bone substitute material for benign and malignant bone defects

Michael Gelinsky, Dresden

10:50 a.m. – 11:10 a.m.

Bortezomib releasing bone substitute materials targeting osteolytic bone disease in multiple myeloma

Dirk Hose, Heidelberg

11:10 a.m. – 12:00 p.m. Coffee break, Snacks included

11:30 a.m. – 12:00 p.m. Coffee and Snacks

11:30 a.m. – 12:00 p.m. Registration

12:00 p.m. – 12:15 p.m.

Introduction, opening remarks for the 6th Heidelberg Myeloma Workshop

Hartmut Goldschmidt, Heidelberg

Anthony D. Ho, Heidelberg

Carsten Müller-Tidow, Heidelberg

Wolfgang Herzog, Heidelberg

12:15 p.m. – 1:15 p.m. KEY NOTE LECTURES

12:15 p.m. – 12:45 p.m.

Introducing Nikhil Munshi (*Marc-Steffen Raab*)

The Myeloma Moonshot – what does it take to cure?

Nikhil Munshi, Boston

12:45 p.m. – 1:15 p.m.

Introducing Pieter Sonneveld (*Hartmut Goldschmidt*)

Multiple myeloma - the European perspective

Pieter Sonneveld, Rotterdam

1:15 p.m. – 2:35 p.m. SESSION I

Biology and Genomics of Multiple Myeloma

*Chairmen: Ola Landgren, New York /Jens Hillengass,
Heidelberg*

1:15 p.m. – 1:35 p.m.

Characterisation of susceptibility genes for the develop- ment of cancer

Richard Houlston, London

1:35 p.m. – 1:55 p.m.

Significance of germline variations for multiple myeloma

Kari Hemminki, Heidelberg



6th Heidelberg Myeloma Workshop

Current status and developments in
diagnosis and therapy of multiple myeloma

1:55 p.m. – 2:15 p.m.

Genetic heterogeneity and genomic evolution in multiple myeloma

Niels Weinhold, Little Rock

2:15 p.m. – 2:35 p.m.

Clinical impact of epigenetics in multiple myeloma

Gareth Morgan, Little Rock

2:35 p.m. – 3:00 p.m. Coffee break

3:00 p.m. – 5:00 p.m. **SESSION II**

Diagnostics and Prognostic Factors

Chairmen: Brian G.M. Durie, Los Angeles/Dirk Hose, Heidelberg

3:00 p.m. – 3:20 p.m.

Role of modern imaging techniques in diagnosis and staging of patients with multiple myeloma

Stefan Delorme, Heidelberg

3:20 p.m. – 3:40 p.m.

Role of modern imaging techniques for prognosis and treatment monitoring

Jens Hillengass, Heidelberg

3:40 p.m. – 4:00 p.m.

Gene-expression profiling- and next generation sequencing in multiple myeloma

Dirk Hose, Heidelberg

4:00 p.m. – 4:20 p.m.

Mutational characterisation of multiple myeloma by investigation of circulating cell free DNA

Andrew Spencer, Melbourne

4:20 p.m. – 4:40 p.m.

Prognostic significance of sequencing-based MRD diagnostics

Bruno Paiva, Pamplona

4:40 p.m. – 5:00 p.m.

Integrating molecular risk markers for stratified medicine

Martin Kaiser, London

5:00 p.m. – 5:20 p.m. Coffee break

5:20 p.m. – 6:20 p.m. **SESSION III**

Role of Immunotherapy in Multiple Myeloma

Chairmen: Gareth Morgan, Little Rock/Christof von Kalle, Heidelberg

5:20 p.m. – 5:40 p.m.

Impact of immune checkpoint blockade

Ashraf Badros, Baltimore

5:40 p.m. – 6:00 p.m.

Targeting multiple myeloma with Car-T-cells-therapy

Henk Lokhorst, Utrecht

6:00 p.m. – 6:20 p.m.

Natural killer cell-based therapy

Adelheid Cerwenka, Heidelberg

6:20 p.m. – 6:30 p.m. **Summary day one**

Hartmut Goldschmidt

7:30 p.m. Evening event



6th Heidelberg Myeloma Workshop

Current status and developments in
diagnosis and therapy of multiple myeloma

Saturday, 6th of May

8:30 a.m. – 10:00 a.m. KEY NOTE LECTURES

8:30 a.m. – 9:00 a.m.
Introducing Brian Durie (*Hartmut Goldschmidt*)
The “Black Swan” research initiative – First results on the way to a cure
Brian G.M. Durie, Los Angeles

9:00 a.m. – 9:30 a.m.
Introducing Ola Landgren (*Jens Hillengass*)
Potential cure by early detection and early treatment
Ola Landgren, New York

9:30 a.m. – 10:00 a.m.
Introducing (*Katja Weisel*)
Role of maintenance treatment in multiple myeloma
Michel Attal, Toulouse

10:00 a.m. – 10:30 a.m. Coffee break

10:30 a.m. – 11:50 a.m. **SESSION IV**
Therapy of Multiple Myeloma – Drugs and Treatment Strategies I
Chairmen: Henk Lokhorst, Utrecht/Christof Scheid, Köln

10:30 a.m. – 10:50 a.m.
Treatment decisions for patients ineligible for transplantation
Heinz Ludwig, Wien

10:50 a.m. – 11:10 a.m.
Optimization of therapy sequence
Michele Cavo, Bologna

11:10 a.m. – 11:30 a.m.
Long term survivors: What can we learn from them?
Saad Usmani, Charlotte

11:30 a.m. – 11:50 a.m.
Personalized therapy in relapsed multiple myeloma
Marc-Steffen Raab, Heidelberg

11:50 a.m. – 12:50 p.m. **SESSION V**
Treatment Paradigm of Multiple Myeloma
*Chairmen: Hartmut Goldschmidt, Heidelberg/
Morie A. Gertz, Rochester*

11:50 a.m. – 12:00 p.m.
Introduction: “Continuous therapy vs. fixed duration of therapy”
Morie A. Gertz, Rochester

12:00 p.m. – 12:20 p.m.
Continuous therapy
Michel Attal, Toulouse

12:20 p.m. – 12:40 p.m.
Fixed duration of therapy
Katja Weisel, Tübingen

12:40 p.m. – 12:50 p.m.
Debate *All*

12:50 p.m. – 1:35 p.m. Lunch Buffet

1:35 p.m. – 2:15 p.m. **SESSION VI**
Gaining insight to the German study groups
Chairmen: Katja Weisel, Tübingen/Heinz Ludwig, Wien

1:35 p.m. – 1:55 p.m.
DSMM – Deutsche Studiengruppe Multiples Myelom
Stefan Knop, Würzburg

1:55 p.m. – 2:15 p.m.
GMMG – German-speaking Myeloma Multicenter Group
Hartmut Goldschmidt, Heidelberg

2:15 p.m. – 3:55 p.m. **SESSION VII**
Therapy of Multiple Myeloma – Drugs and Treatment Strategies II
*Chairmen: Marc-Steffen Raab, Heidelberg/
Michel Attal, Toulouse*



6th Heidelberg Myeloma Workshop

Current status and developments in
diagnosis and therapy of multiple myeloma

2:15 p.m. – 2:35 p.m.

Significance of allogeneic stem cell transplantation

Nicolaus Kröger, Hamburg

2:35 p.m. – 2:55 p.m.

Single vs. double transplantation

Roman Hajek, Ostrava

2:55 p.m. – 3:15 p.m.

Immunomodulatory drugs in the treatment of multiple myeloma

Anders Waage, Trondheim

3:15 p.m. – 3:35 p.m.

Improvement of therapy of multiple myeloma with new proteasome inhibitors

Christof Scheid, Köln

3:35 p.m. – 3:55 p.m.

Monoclonal antibody-based therapies – the newest developments

Torben Plesner, Vejle

3:55 p.m. – 16:00 p.m. Summary of the 6th Heidelberg Myeloma Workshop

Hartmut Goldschmidt, Heidelberg

Organisation and Congress venue

5th and 6th May 2017

Congress venue

Pre Conference Scientific Workshop on bone metabolism and bone substitute materials

(related to SFB Transregio 79)

National Center for Tumor Diseases

Room K2/K3

Im Neuenheimer Feld 460

69120 Heidelberg

6th Heidelberg Myeloma Workshop

Medizinische Klinik Heidelberg

Lecture Hall

Im Neuenheimer Feld 410

69120 Heidelberg

Contact and registration

Katja Weisert

Sektion Multiples Myelom

Medizinische Klinik V

Universitätsklinikum Heidelberg

Phone: +49 6221 56-5427

Fax: +49 6221 56-5647

E-Mail: katja.weisert@med.uni-heidelberg.de

Or register online at:

www.myelomaworkshop.de

Janssen-Cilag GmbH
41470 Neuss
50.000 Euro

